文献速递胸部肿瘤

PHAROS II期研究更新:Encorafenib联合Binimetinib治疗BRAF V600E突变转移性NSCLC的OS分析

Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2025-10-19

PHAROS II期研究纳入98例BRAF V600E突变转移性NSCLC患者(59例初治,39例经治),接受encorafenib 450 mg每日一次联合binimetinib 45 mg每日两次治疗。更新随访显示初治组中位OS为47.6个月(95% CI 31.3至不可估计),4年OS率49%;经治组中位OS为22.7个月(95% CI 14.1至32.6),4年OS率31%。安全性特征与既往分析一致。

要点

  • 初治患者中位OS达47.6个月,4年OS率49%
  • 经治患者中位OS为22.7个月,4年OS率31%
  • 安全性特征与既往分析一致,未报告新安全性信号

核心结论

  • 在初治BRAF V600E突变转移性NSCLC患者中,encorafenib联合binimetinib与迄今靶向治疗报告的最长中位OS相关。

研究设计与样本

  • II期PHAROS研究纳入98例BRAF V600E突变转移性NSCLC患者,其中初治59例、经治39例。
  • 患者接受encorafenib 450 mg每日一次联合binimetinib 45 mg每日两次治疗,本次更新数据截止日期为2025年3月14日。

主要发现

  • 初治组中位随访OS 52.3个月,中位OS为47.6个月(95% CI 31.3至不可估计),4年OS率为49%(95% CI 35至62)。
  • 经治组中位随访OS 48.2个月,中位OS为22.7个月(95% CI 14.1至32.6),4年OS率为31%(95% CI 16至47)。
  • 初治组和经治组分别有58%和26%的患者接受了至少一种后续系统性抗肿瘤治疗。
  • 安全性特征与既往分析一致。

临床怎么用

  • 对于初治BRAF V600E突变转移性NSCLC患者,encorafenib联合binimetinib可作为靶向治疗选择,需注意跨试验比较应谨慎。

局限性

  • 原文指出跨试验比较应谨慎进行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The phase II PHAROS study previously showed that encorafenib plus binimetinib has antitumor activity in patients with BRAF V600E-mutant metastatic non-small cell lung cancer (mNSCLC). In PHAROS, 98 patients (59 treatment-naïve; 39 previously treated) received encorafenib 450 mg once daily and binimetinib 45 mg twice daily. We report updated results from data cutoff of March 14, 2025. The median duration of treatment with both encorafenib and binimetinib was 16.3 months in treatment-naïve and 5.5 months in previously treated patients. After median follow-up for overall survival (OS) of 52.3 months in treatment-naïve patients, mOS was 47.6 months (95% CI, 31.3 to not estimable); 4-year OS probability was 49% (95% CI, 35 to 62). After median follow-up for OS of 48.2 months in previously treated patients, mOS was 22.7 months (95% CI, 14.1 to 32.6); 4-year OS probability was 31% (95% CI, 16 to 47). In treatment-naïve and previously treated groups, 58% and 26% received ≥1 subsequent systemic anticancer treatment, respectively. Safety profile remained consistent with that in previous analyses. Although comparisons across trials should be done cautiously, to our knowledge, encorafenib plus binimetinib was associated with the longest mOS reported to date with targeted treatment in patients with treatment-naïve BRAF V600E-mutant mNSCLC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Johnson ML, Smit EF, Felip E, et al. Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer. J Clin Oncol. 2025. PMID: 41109959. doi:10.1200/JCO-25-02023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。